摘要:
Novel compound represented by the formula: ##STR1## wherein A", B, C, D, E, G, Ar, X, Y, and Z are defined herein or a salt thereof. The compounds have excellent activity of inhibiting ACAT, lowering Cholesterol in blood and inhibiting tachykinin receptor, or a salt thereof, their production and use.
摘要:
Novel compound represented by the formula: ##STR1## such as 6-Chloro-N-(2,6-diethoxyphenyl)-4-(2-methylphenyl-2-oxo-2H-1-benzopyran-3-acetamide: ##STR2## or a salt thereof. The compound has an excellent activity of inhibiting ACAT, lowering the cholesterol in blood and inhibiting tachykinin receptor. The present invention also relates to the production and use of the disclosed compound.
摘要:
A novel compound represented by the formula: ##STR1## wherein Ring A and Ring B respectively stands for an optionally substituted homo- or hetero-cyclic ring, and at least one of them stands for an optionally substituted heterocyclic ring stand; Ring C stands for an optionally substituted benzene ring; R stands for a hydrogen atom or an optionally substituted hydrocarbon residue; one of X and Y stands for --NR.sup.1 -- (R.sup.1 stands for a hydrogen atom or an optionally substituted hydrocarbon residue) or --O--, and the other stands for--CO-- or --CS--, or one of them stands for --N.dbd. and the other stands for .dbd.CR.sup.2 -- (R.sup.2 stands for a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon residue, an optionally substituted amino group or an optionally substituted hydroxyl group); n denotes 1 or 2 or salts thereof which have an excellent tachykinin receptor antagonistic action and inhibitory action on plasma extravasation.
摘要:
Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.C
摘要翻译:下列通式的新化合物或其盐。 其中环M是具有-N = C,-CO-N或-CS-N(作为部分结构-X + E,ov)的杂环。 。 + EE Y < R a和R b彼此键合形成环A,或它们相同或不同,独立地表示环M上的氢原子或取代基; 环A和环B独立地表示任选取代的杂环或杂环,并且它们中的至少一个是任选取代的杂环; R C是任选取代的杂环或杂环; R Z是任选取代的环; n表示1〜6的整数,或其盐具有优异的速激肽受体拮抗作用及其制备及药物组合物。
摘要:
Novel composition represented by the formula: ##STR1## wherein ring A and ring B each means a benzene ring which may be substituted; R means a hydrogen atom or an alkyl group which may be substituted; R.sup.1 means a hydrogen atom or an alkyl group which may be substituted; R.sup.2 means a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted, or R.sup.1 and R.sup.2, taken together with the adjacent nitrogen atom, jointly form a ring which may be substituted, or a pharmaceutically acceptable salt thereof which is a useful tachykinin receptor antagonist.
摘要翻译:由下式表示的新型组合物:其中环A和环B各自表示可被取代的苯环; R表示氢原子或可被取代的烷基; R1表示氢原子或可被取代的烷基; R 2表示可以被取代的烃基或可被取代的杂环基,或者R 1和R 2与相邻的氮原子一起形成可被取代的环,或其药学上可接受的盐,其是有用的 速激肽受体拮抗剂。
摘要:
In a non-aqueous electrolyte secondary battery, in order to adjust a cathode active material in which guest cation such as Na and Li is included, alkaline metal fluoride which is expressed by a general formula AF and transition metal fluoride which is expressed by a formula M′ F2 are subjected to a mechanical milling process to produce metal fluoride compound AM′ F3. The mechanical milling process desirably uses a planetary ball mill.
摘要:
Disclosed is a labeling substance capable of reversibly immobilizing (reversible detachment) to a solid surface and to reliably and accurately identify a target biological substance interacting with a probe substance bound to the labeling substance. A chimeric compound is provided, which includes a labeling substance L including (1) an organic compound S with a chemical structure capable of binding to a probe substance P, which can interact with a biological substance B and (2) a peptide bound to the organic compound S and specifically recognized by an antibody A, peptide and a probe substance P at least except a peptide or protein. In addition, a method for preparing the labeling substance L and a method for capturing, structurally analyzing and/or identifying the biological substance using the labeling substance L are provided.